GLP-1s may cut risk of obesity-related cancers: 3 study notes  

A new study has found GLP-1s may reduce the risk of developing obesity-related cancers by 41% compared to bariatric surgery — a benefit researchers believe could be tied to the drugs’ ability to reduce inflammation.  The findings, published May 11 in The Lancet’s eClinicalMedicine journal, are based on data from more than 6,000 adults. Researchers […]

The Drug Pricing Scramble – OpEd

For the same pharmaceutical products, US prices can be anywhere between two and ten times higher in US markets compared to prices across the border. Nor is importation allowed, even though this would drive prices toward equilibrium by facilitating market competition. This problem has persisted for decades. US taxpayers and health insurance subscribers subsidize pharmaceutical […]

Azapeptide-based GLP-1 receptor agonist improves glucose metabolism in a diet-induced obesity model

Peptidomimetics, synthetically modified peptides which have been engineered to eliminate certain undesirable features of native therapeutic peptides including short half-lives, immunogenicity, and delivery challenges, are a growing class of peptide-based therapeutics. Azapeptides (C to N substitution(s)), a type of peptidomimetic with several examples in clinical use, are known to exhibit increased resistance to endogenous proteases, […]

Lost it on Wegovy? You might gain it all back in a year

A recent study presented at the European Congress on Obesity reveals that individuals using weight loss drugs, including newer GLP-1 medications, tend to regain all lost weight within a year of discontinuing the medication. While these drugs effectively induce weight loss, maintaining a healthy lifestyle through diet and exercise remains crucial for long-term success.

Will Trump’s Executive Order Lower Prescription Drug Prices?

The cost of prescription drugs in the U.S. has long outpaced that of peer nations, a dynamic driven by a combination of regulatory gaps, market forces, and lobbying pressure. Now, President Donald Trump is once again trying to tackle the issue—this time through an Executive Order that aims to pressure pharmaceutical companies to voluntarily lower […]